Beijing News (Reporter Zhang Xiulan) On January 20, Changchun High-tech dropped by the limit once more. After the news that the core product recombinant human growth hormone was included in the centralized procurement on the 19th, Changchun High-tech has fallen for two consecutive times. On January 20, Changchun Hi-Tech’s board secretary answered investors’ questions on the interactive platform, saying that the bidding process for this centralized procurement has not yet officially started, and the degree of impact on the company is still uncertain.
On January 20, Changchun Hi-Tech closed at 204.84 yuan per share, the limit fell for two consecutive days, and its market value also fell below the 100 billion mark, falling to 82.903 billion yuan. The inclusion of growth hormone in the scope of centralized procurement is considered to be an important reason for the decline of Changchun High-tech. On January 19, the official website of the Guangdong Provincial Drug Trading Center issued a notice on the “Guangdong Alliance Diclofenac and Other Drugs Procurement Documents” (hereinfollowing referred to as “Procurement Documents”), and announced the centralized procurement of diclofenac and other 276 drugs. It includes Changchun Hi-Tech’s blockbuster product recombinant human growth hormone.
Changchun Hi-Tech’s board secretary said on January 20 when answering questions from investors that the bidding process for this centralized drug purchase has not yet officially started, and the specific impact will also depend on the actual participation in the bidding, the results of the selection, and the selection price. Subsequent events and the degree of impact on the company are still uncertain, and there is currently no expectation that it will have a serious impact on the company’s operating performance.
Judging from the procurement documents, the main body of this procurement is all public medical institutions (including military medical institutions) in the alliance area. Medical insurance designated social medical institutions and designated pharmacies can participate voluntarily. The alliance areas include Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps.
The total amount of pre-purchase in the first year of the procurement period of the public medical institutions in the alliance area is 8247689IU, of which powder injection and water injection account for regarding 60% and 40% respectively. Dongguan SecuritiesIn the research report, it is stated that from the perspective of the highest effective declared price, the maximum price of growth hormone powder injection is relatively optimistic, and powder injection-related companies are likely to actively bid.
Proofreading Lucy Return to Sohu, see more
Editor:
Statement: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.
